'U.S. Prepares For Possible Arrival Of More Severe Strain Of Mpox; There Have Been Nearly 25,000 Cases Of The Clade 1 Version Of Mpox In Africa So Far This Year" - NBC
Portfolio Pulse from Benzinga Newsdesk
The U.S. is preparing for the potential arrival of a more severe strain of mpox, clade 1, which has caused significant cases and deaths in Africa. The government is enhancing surveillance and testing, and the Jynneos vaccine is available for high-risk groups. Efforts are underway to develop new treatments, although current options like TPOXX are ineffective against clade 1.
September 06, 2024 | 6:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Chimerix, involved in antiviral treatments, may face challenges as TPOXX, a related antiviral, is ineffective against clade 1 mpox. This could impact CMRX's stock negatively if no effective treatments are developed.
CMRX is involved in antiviral treatments, and the ineffectiveness of TPOXX against clade 1 mpox highlights the challenge in developing effective treatments. This could negatively impact CMRX if no new solutions are found.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60
POSITIVE IMPACT
Emergent BioSolutions, which produces the Jynneos vaccine effective against mpox, may see increased demand as the U.S. prepares for the clade 1 strain. The government's assurance of sufficient vaccine supply could positively impact EBS.
EBS produces the Jynneos vaccine, which is effective against both clade 1 and clade 2 mpox strains. As the U.S. prepares for potential cases of the more severe clade 1, demand for the vaccine may increase, positively impacting EBS's business.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80